Want to see AU:PHX full AI Analyst Report?
Top Page
PharmX Technologies
(Sydney:PHX)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.10
▼(-3.00% Downside)
Action:N/A
Date:08/28/26
The score is pressured primarily by worsening profitability in 2026 (revenue decline, negative gross margin, and larger losses) and a bearish technical setup (price below key moving averages with negative MACD). Balance-sheet strength and improved 2026 operating/free cash flow provide some support, but valuation is difficult to justify with a negative P/E and no dividend yield data.
Positive Factors
Low Leverage
Very low leverage reduces financial risk and interest burden, giving PharmX greater flexibility to fund operations or adjust strategy while it works to restore profitability.
Negative Factors
Revenue Contraction
A significant revenue decline signals weakening demand, customer traction, or execution. If sustained, lower scale can reduce operating leverage and make it harder for PharmX to support investment and reach profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage reduces financial risk and interest burden, giving PharmX greater flexibility to fund operations or adjust strategy while it works to restore profitability.
Read all positive factors
PharmX Technologies (PHX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$66.61M
Dividend YieldN/A
Average Volume (3M)1.01M
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth4.06%
EPS Growth-625.00%
CountryAU
Employees9
SectorHealthcare
Sector Strength45
IndustryInformation Technology Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding666,118,650
10 Day Avg. Volume421,582
30 Day Avg. Volume1,005,256
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.46
Price to Sales (P/S)10.58
P/FCF Ratio100.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PharmX Technologies Business Overview & Revenue Model
Company Description
PharmX Technologies Limited, together with its subsidiaries, operates as a technology and software development company in Australia. It also operates PharmX, an electronic ordering and invoicing gateway; PharmX Marketplace, an e-commerce ordering ...
PharmX Technologies Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
78
Positive
Cash Flow
55
Neutral
| Breakdown | Jun 2025 | Jun 2024 |
|---|---|---|
Income Statement | ||
| Total Revenue | 7.62M | 7.32M |
| Gross Profit | -70.00K | 5.96M |
| EBITDA | -532.00K | 1.39M |
| Net Income | -1.83M | -264.00K |
Balance Sheet | ||
| Total Assets | 27.27M | 18.82M |
| Cash, Cash Equivalents and Short-Term Investments | 2.57M | 4.17M |
| Total Debt | 540.00K | 894.00K |
| Total Liabilities | 3.99M | 2.90M |
| Stockholders Equity | 23.28M | 15.93M |
Cash Flow | ||
| Free Cash Flow | 805.00K | -8.16M |
| Operating Cash Flow | 825.00K | -8.13M |
| Investing Cash Flow | -2.10M | -695.00K |
| Financing Cash Flow | -322.00K | -136.00K |
PharmX Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$128.98M | 57.06 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$38.07M | -6.00 | -14.19% | ― | 2.08% | -195.31% | |
47 Neutral | AU$20.74M | ― | -578.72% | ― | 113.42% | 29.17% | |
44 Neutral | AU$66.61M | -40.00 | -7.55% | ― | 4.06% | -625.00% | |
44 Neutral | AU$19.65M | -2.68 | -1009.84% | ― | 11.45% | 0.69% | |
37 Underperform | AU$8.93M | -0.16 | -1566.68% | ― | -71.80% | -1044.71% |
* Healthcare Sector Average
AU:PHX
PharmX Technologies
0.10
-0.02
-16.67%
AU:BMT
Beamtree Holdings Ltd
0.12
-0.12
-50.00%
AU:AHE
MedAdvisor Limited
0.01
-0.04
-73.08%
AU:ALC
Alcidion Group Limited
0.10
>-0.01
-3.00%
AU:ICR
InteliCare Holdings Limited
0.03
<0.01
62.50%
AU:PCK
PainChek Ltd
0.09
-0.30
-75.90%
PharmX Technologies Corporate Events
PharmX Technologies Outlines FY26 Results with Strong Investor Disclaimers
Aug 27, 2026
PharmX Technologies has released an investor presentation outlining its FY26 results, positioning the document strictly as informational rather than an offer to buy or sell securities. The company stresses that the material is not a prospectus or ...
Pharmx Builds Momentum on Sigma Alliance and Marketplace Growth
Aug 26, 2026
Pharmx reported FY26 revenue of $7.7 million, up 3% year on year, with strong growth in recurring marketplace and analytics revenue but lower EBITDA of $1.1 million due to planned investment in its new Marketplace launch and the Sigma alliance. Gr...
PharmX Technologies Strengthens Governance Framework in Line with ASX Standards
Aug 26, 2026
PharmX Technologies has updated its corporate governance statement, confirming compliance in all material respects with the fourth edition of the ASX Corporate Governance Council’s principles and outlining the roles and responsibilities of t...
PharmX Technologies Posts Loss Despite Revenue Growth and Stronger Asset Base
Aug 26, 2026
PharmX Technologies Limited reported a 2.7% increase in revenues from ordinary activities to $7.7 million for the year ended 30 June 2026, while net profit attributable to owners plunged to a loss of $1.8 million, representing a sharp 591.7% deter...
PharmX Technologies Sets Date for 2026 Annual Results and Investor Webinar
Aug 20, 2026
PharmX Technologies Limited has scheduled the release of its annual report for the year ended 30 June 2026 on Thursday, 27 August 2026, underscoring a key disclosure event for investors in the ANZ pharmacy technology space. The timing signals the ...
PharmX Issues New Shares to Sigma Subsidiary Under Strategic Alliance
Jul 10, 2026
PharmX Technologies has issued 6,661,187 fully paid ordinary shares to CW Retail Holdings, a subsidiary of Sigma Healthcare, under the existing Strategic Alliance Agreement between the two companies. The issuance was undertaken without a prospectu...
PharmX Issues Additional Shares to Sigma Subsidiary, Strengthening Strategic Ties
Jul 10, 2026
PharmX Technologies Limited has issued 6,661,187 new fully paid ordinary shares to CW Retail Holdings Pty Ltd, a subsidiary of Sigma Healthcare, following the execution of a Deed of Amendment effective 10 July 2026. The issuance supplements an ini...
PharmX Technologies Confirms Sigma Healthcare’s 10% Strategic Stake
Jul 10, 2026
PharmX Technologies has completed the final step in its strategic alliance with Sigma Healthcare, confirming Sigma’s move to a full 10% shareholding in the pharma-tech company. Sigma initially subscribed for nearly 60 million shares, giving ...
Pharmx Secures Two-Year Renewal of Exclusive NDSS Agreement
Jul 6, 2026
Pharmx Technologies has renewed its long-standing exclusive agreement with Australia’s National Diabetes Services Scheme for a further 24 months starting 1 July 2026, cementing its status as critical digital infrastructure in the national he...
Pharmx expands Sigma alliance with NZ supply-chain gateway rollout
Jun 29, 2026
Pharmx Technologies has secured the first work item under its multi-year Strategic Alliance with Sigma Healthcare, launching a vertically integrated Gateway solution to support Sigma’s new South Auckland distribution centre from September 20...
Pharmx to Spotlight Growth Strategy at Planet MicroCap Conference
Jun 17, 2026
Pharmx Technologies Limited, a pharmacy technology provider in Australia and New Zealand, operates a high-availability ordering and inventory management platform that links pharmacies, suppliers and technology vendors, processing roughly $20 billi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.